Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: AD-2111Drug: AD-2112
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04375865
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
Phase 2
Completed
- Conditions
- Hypertension,Essential
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT04218552
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
To Evaluate the Pharmacokinetics and Safety of AD-208
Phase 1
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: AD-208Drug: Avodart Soft Capsule 0.5mg
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04214808
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
Phase 3
Completed
- Conditions
- HypertensionHypercholesterolemia
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT04158076
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-203
Phase 3
Completed
- Conditions
- Acute GastritisChronic Gastritis
- Interventions
- Drug: AD-203Drug: Mucosta tab.
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 475
- Registration Number
- NCT04066530
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole
Phase 1
Completed
- Conditions
- Gastritis
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03980756
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
Phase 3
Completed
- Conditions
- HypertensionHypercholesterolemia
- Interventions
- Drug: Ezetimibe/RosuvastatinDrug: Telmisartan
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT03872232
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: Raloxifene 60mg/Cholecalciferol 800IUDrug: AD-102
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03824171
- Locations
- 🇰🇷
Korea University Guro Hosptial, Seoul, Korea, Republic of
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03764462
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
Phase 1
Completed
- Conditions
- HyperlipidemiasHypertension
- Interventions
- Drug: AD-2071 10/20mgDrug: AD-2072 80/5mgDrug: AD-2071 10/20mg + AD2072 80/5mg
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03632668
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath